Company: IXHL
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029414
Chunk: 24

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 24
---
 recent Annual Report on Form 10-K and in our Quarterly Reports on Form 10-Q for the quarterly
periods ended subsequent to our filing of such Annual Report on Form 10-K, as well as any amendments thereto and other documents we filed
with the SEC and reflected in subsequent filings with the SEC.

Also, these forward-looking
statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required
by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.
Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking
statements. You should read this prospectus supplement, the accompanying prospectus, together with the documents that we have filed with
the SEC that are incorporated by reference herein and therein and any free writing prospectus we have authorized for use in connection
with this offering, completely and with the understanding that our actual future results may be materially different from what we expect.
We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements.

<div align='center'>S-11

USE
OF PROCEEDS</div>

We may issue and sell shares
of our common stock having aggregate sales proceeds of up to $16,768,099 from time to time. Because there is no minimum offering amount
required as a condition to close this offering, the actual total public offering amount, sales agent commissions and proceeds to us, if
any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the Sales Agreement
with A.G.P. as a source of financing.

We currently intend to use
the net proceeds from this offering, if any, for working capital and general corporate purposes. We may also use a portion of the net
proceeds to in-license, invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although
we have no current plans, commitments or agreements with respect to any acquisitions. Pending these uses, we intend to invest the net
proceeds, if any, in short- and intermediate-term, investment-grade, interest-bearing securities. We will retain broad discretion in determining
how we will allocate the net proceeds from the sale of common stock under this prospectus supplement and the accompanying prospectus.

<div align='center'>S-12

DILUTION</div>

If you